These results strongly support our hypothesis that panobinostat synergistically enhanced the anti-tumor activity of etoposide, doxorubicin, or cisplatin while down-regulating CHK1 and preventing activation of the G2 cell cycle checkpoint. The gene discussed is CHEK1; the disease is neoplasm.